Abstract
The authors summarized the evidence supporting neuroprotection based on the data available in the literature. In vivo and in vitro studies have indicated that many compounds can decrease neurodegeneration, excitotoxicity, oxidative stress, protein aggregation, disturbance of Ca2+ homeostasis and compensate the energy impairment. Selegiline, rasagiline, dopamine agonists and other molecules (ubiquinone, kynurenic acid, tocopherol, creatine, glatiramer acetate) exert neuroprotective effects in preclinical studies. Much less clinical data are available regarding neuroprotection in different neurological disorders. In this review, such preclinical and clinical evidences are summarized.
MeSH terms
-
Animals
-
Creatine / pharmacology
-
Creatine / therapeutic use
-
Dopamine Agonists / pharmacology
-
Dopamine Agonists / therapeutic use
-
Glatiramer Acetate
-
Humans
-
Indans / pharmacology
-
Indans / therapeutic use
-
Kynurenic Acid / pharmacology
-
Kynurenic Acid / therapeutic use
-
Micronutrients / pharmacology
-
Micronutrients / therapeutic use
-
Nerve Degeneration / drug therapy*
-
Neurodegenerative Diseases / drug therapy*
-
Neuroprotective Agents / pharmacology*
-
Neuroprotective Agents / therapeutic use*
-
Oxidative Stress / drug effects
-
Parkinson Disease / drug therapy*
-
Peptides / pharmacology
-
Peptides / therapeutic use
-
Selegiline / pharmacology
-
Selegiline / therapeutic use
-
Tocopherols / pharmacology
-
Tocopherols / therapeutic use
-
Ubiquinone / pharmacology
-
Ubiquinone / therapeutic use
Substances
-
Dopamine Agonists
-
Indans
-
Micronutrients
-
Neuroprotective Agents
-
Peptides
-
rasagiline
-
Ubiquinone
-
Selegiline
-
Glatiramer Acetate
-
Kynurenic Acid
-
Creatine
-
Tocopherols